110 related articles for article (PubMed ID: 28456932)
21. Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways.
Shen A; Lin J; Chen Y; Lin W; Liu L; Hong Z; Sferra TJ; Peng J
Oncol Rep; 2013 Oct; 30(4):1701-6. PubMed ID: 23843018
[TBL] [Abstract][Full Text] [Related]
22. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model.
Abramson LP; Stellmach V; Doll JA; Cornwell M; Arensman RM; Crawford SE
J Pediatr Surg; 2003 Mar; 38(3):336-42; discussion 336-42. PubMed ID: 12632345
[TBL] [Abstract][Full Text] [Related]
23. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
24. Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model.
Yan X; Chen H; Lu X; Wang F; Xu W; Jin H; Zhu P
Eur J Pharm Sci; 2011 Jul; 43(4):251-9. PubMed ID: 21569843
[TBL] [Abstract][Full Text] [Related]
25. Anti-angiogenic and apoptotic effects of metabolites of sulindac on chick embryo chorioallantoic membrane.
Elwich-Flis S; Sołtysiak-Pawluczuk D; Spławiński J
Hybrid Hybridomics; 2003 Feb; 22(1):55-60. PubMed ID: 12713691
[TBL] [Abstract][Full Text] [Related]
26. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
27. Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice.
Gil M; Skopińska-Rózewska E; Radomska D; Demkow U; Skurzak H; Rochowska M; Beuth J; Roszkowski K
Folia Biol (Praha); 1993; 39(2):63-8. PubMed ID: 7504997
[TBL] [Abstract][Full Text] [Related]
28. Characterization of matrix metalloproteinase inhibitors: angiogenesis and tumor models.
Albert DH; Davidsen SK
Curr Protoc Pharmacol; 2001 Aug; Chapter 5():Unit5.23. PubMed ID: 21959760
[TBL] [Abstract][Full Text] [Related]
29. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer.
Shanmugam MK; Warrier S; Kumar AP; Sethi G; Arfuso F
Curr Vasc Pharmacol; 2017; 15(6):503-519. PubMed ID: 28707601
[TBL] [Abstract][Full Text] [Related]
30. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of pro-angiogenic factors by a lipid-rich shark extract.
Yuan L; Yoshida M; Davis PF
J Med Food; 2006; 9(3):300-6. PubMed ID: 17004890
[TBL] [Abstract][Full Text] [Related]
32. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
33. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
34. Search for Anti-angiogenic Substances from Natural Sources.
Kotoku N; Arai M; Kobayashi M
Chem Pharm Bull (Tokyo); 2016; 64(2):128-34. PubMed ID: 26833441
[TBL] [Abstract][Full Text] [Related]
35. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
36. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
37. Abrus agglutinin is a potent anti-proliferative and anti-angiogenic agent in human breast cancer.
Bhutia SK; Behera B; Nandini Das D; Mukhopadhyay S; Sinha N; Panda PK; Naik PP; Patra SK; Mandal M; Sarkar S; Menezes ME; Talukdar S; Maiti TK; Das SK; Sarkar D; Fisher PB
Int J Cancer; 2016 Jul; 139(2):457-66. PubMed ID: 26914517
[TBL] [Abstract][Full Text] [Related]
38. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
39. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.
Lai KC; Hsu SC; Yang JS; Yu CC; Lein JC; Chung JG
J Cell Mol Med; 2015 Feb; 19(2):474-84. PubMed ID: 25403643
[TBL] [Abstract][Full Text] [Related]
40. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
